BCP
TAK icon

BSN Capital Partners’s Takeda Pharmaceutical TAK Stock Holding History

BSN Capital Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,680,000
Closed -$63.8M – 17
2021
Q4 		$63.8M Buy
+4,680,000
New +$65.6M 4.05% 8

Other funds holding TAK

PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BSN Capital Partners's TAK Position: Q1 2022 in Review

BSN Capital Partners sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 4,680,000 shares — an estimated $63.8M sold.

BSN Capital Partners first reported a position in TAK in Q4 2021 and held it in 1 quarter. The position peaked at $63.8M in Q4 2021. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

  • BSN Capital Partners reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
  • BSN Capital Partners sold 4,680,000 Takeda Pharmaceutical shares in Q1 2022, an estimated $63.8M.
  • BSN Capital Partners first reported a position in Takeda Pharmaceutical in Q4 2021 and held it in 1 quarter.
  • BSN Capital Partners's Takeda Pharmaceutical position peaked at $63.8M in Q4 2021.
  • 288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on BSN Capital Partners's 13F filing for Q1 2022.